The Crypto That’s Making Wall Street Sweat

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Miles Mchugh Biography and Net Worth

SVP of Horizon Therapeutics Public

Miles W McHugh Net Worth

Net worth is estimated to be at least $27.44M
Owns at least 36,521 units of Horizon Therapeutics Public Ltd Co stock
Sold an estimated value of $17.1M in the last 7 years at Horizon Therapeutics Public Ltd Co

Miles W McHugh Trading

Largest purchase of shares was 79,484 units, worth over $1.76M on December 3, 2021
Largest sale of shares was 79,484 units, worth over $8.47M on December 3, 2021
In total has made about 26 transactions over 7 years
Usually trades in January, with the busiest year in 2020

What is Miles W. Mchugh's net worth?: The estimated net worth of Miles W. Mchugh is at least $2.30 million as of December 14th, 2020. Mchugh owns 19,741 shares of Horizon Therapeutics Public stock worth more than $2,295,878 as of November 15th. This net worth evaluation does not reflect any other assets that Mchugh may own. Learn More about Miles W. Mchugh's net worth.
How do I contact Miles W. Mchugh?: The corporate mailing address for Mchugh and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Miles W. Mchugh's contact information.
Has Miles W. Mchugh been buying or selling shares of Horizon Therapeutics Public?: Miles W. Mchugh has not been actively trading shares of Horizon Therapeutics Public during the last quarter. Most recently, Miles W. Mchugh sold 1,856 shares of the business's stock in a transaction on Monday, December 14th. The shares were sold at an average price of $80.00, for a transaction totalling $148,480.00. Following the completion of the sale, the senior vice president now directly owns 19,741 shares of the company's stock, valued at $1,579,280. Learn More on Miles W. Mchugh's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Miles W. Mchugh Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/14/2020	Sell	1,856	$80.00	$148,480.00	19,741
11/12/2020	Sell	12,124	$75.48	$915,119.52	21,597
5/11/2020	Sell	49,114	$44.22	$2,171,821.08	125,296
5/8/2020	Sell	45,366	$43.51	$1,973,874.66	125,296
5/5/2020	Sell	5,007	$37.00	$185,259.00	132,640
2/27/2020	Sell	1,000	$34.34	$34,340.00	137,647

Miles W. Mchugh Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield